621,625 Shares in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Bought by Renaissance Technologies LLC

Renaissance Technologies LLC bought a new stake in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 621,625 shares of the biopharmaceutical company’s stock, valued at approximately $727,000. Renaissance Technologies LLC owned approximately 1.13% of Marinus Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Avoro Capital Advisors LLC increased its holdings in shares of Marinus Pharmaceuticals by 31.4% during the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after acquiring an additional 990,607 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Marinus Pharmaceuticals by 5.0% in the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after purchasing an additional 132,689 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter worth $813,000. Wellington Management Group LLP boosted its holdings in shares of Marinus Pharmaceuticals by 54.8% during the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock worth $2,623,000 after buying an additional 85,455 shares during the period. Finally, Hussman Strategic Advisors Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 10,500 shares during the period. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Stock Down 5.9 %

MRNS opened at $1.74 on Wednesday. The company has a market capitalization of $95.59 million, a P/E ratio of -0.66 and a beta of 1.14. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15. The firm’s fifty day moving average price is $1.45 and its two-hundred day moving average price is $2.21. Marinus Pharmaceuticals, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The business had revenue of $8.06 million for the quarter, compared to analyst estimates of $9.05 million. During the same quarter last year, the firm posted ($0.61) earnings per share. On average, analysts anticipate that Marinus Pharmaceuticals, Inc. will post -1.88 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 24th. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Truist Financial reiterated a “buy” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. StockNews.com upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 4th. Finally, Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a research note on Monday, September 23rd. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $8.83.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.